Document:

Non-Exclusive License Agreement

 Exhibit 10.27 
 CONFIDENTIAL TREATMENT REQUESTED 
 Portions of this Exhibit have been redacted
pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended. Such redacted portions have been replaced with “***” in this
Exhibit. An unredacted version of this document has been filed separately with the Securities and Exchange Commission along with the request for confidential treatment 
 NON-EXCLUSIVE LICENSE AGREEMENT 
 This Non-Exclusive License Agreement
(this “Agreement”) is entered into this 27th day of March, 2012 (the “Effective Date”), by and between Caliper Life Sciences Corporation, a Delaware corporation having a principal place of business at 68 Elm Street, Hopkinton, MA
01748 (“Licensor”), and Clinical Micro Sensors, Inc. d/b/a GenMark Diagnostics, Inc., a Delaware corporation having a principal place of business at 5964 La Place Court, Carlsbad, CA 92008 (“Licensee”), each also referred to
herein individually as a “Party” and collectively as “Parties.” 
 WHEREAS, Licensor is engaged in research,
development and commercialization efforts towards the miniaturization, integration and automation of laboratory equipment, and owns certain patent rights associated therewith; 
 WHEREAS, Licensee is engaged in the research, development and commercialization of Microfluidics Technology (as defined below) including instruments, software and microfluidic chips; 

WHEREAS, the Parties wish to fully and finally resolve all patent issues associated with the aforementioned microfluidics patent rights,
upon the terms and subject to the conditions set forth below, and thereby avoid the substantial costs, uncertainty and risk involved with prolonged patent-infringement litigation, trial and appeal; 

WHEREAS, Licensee desires to obtain and Licensor desires to grant to Licensee a non-exclusive license to certain patent rights of
Licensor for the research, development and commercialization of certain devices and instruments for use in the Field. 
 NOW,
THEREFORE, in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 

 

	1.	DEFINITIONS. 

  

	 	1.1	Affiliate(s). “Affiliate(s)” shall mean any person or entity which controls, is controlled by or is under common control with a Party. For the purposes
of this Section 1.1, “control” means (a) it owns or controls at least fifty percent (50%) of the equity securities of entity Party and is entitled to vote such securities in the election of directors (or, in the case of an
entity that is not a corporation, for the election of the corresponding managing authority), or (b) it has the power to directly or indirectly direct or cause the direction of the board of directors or equivalent governing body of entity Party.

  

	 	1.2	Calendar Quarter. “Calendar Quarter” shall mean the respective periods of three (3) consecutive calendar months ending on
March 31, June 30, September 30 or December 31. 

  

	 	1.3	Calendar Year. “Calendar Year” shall mean the periods of twelve (12) consecutive calendar months ending on December 31.

	 	1.4	Change of Control. “Change of Control” shall mean, with respect to the Licensee, any merger or other transaction or series of transactions
(a) which results in the holders of voting securities of Licensee outstanding immediately prior thereto failing to continue to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more
than fifty percent (50%) of the combined voting power of the voting securities of Licensee outstanding immediately after such merger or transaction or series of transactions, or (b) in which a Third Party acquires all or substantially all
of Licensee’s business, capital stock outstanding, or assets to which this Agreement applies, whether by merger, acquisition, sale, or otherwise. 

  

	 	1.5	Combination Product. “Combination Product” shall mean a product or combination of products, sold, transferred or otherwise disposed of at a single
price, that contains or consists of a Licensed Product and at least one other product that is not a Licensed Product. 

  

	 	1.6	Confidential Information. “Confidential Information” shall mean any information provided to Licensor pursuant to Article 3 of this Agreement, and the
terms of this Agreement. 

  

	 	1.7	Control or Controlled. “Control” or “Controlled” shall mean, with respect to any intellectual property right (including any Patent Rights),
the possession (whether by ownership or license, or otherwise) by a Party of the ability to grant to the other Party a license or other right as provided herein under such intellectual property without violating the terms of any written agreement
existing before the Effective Date with a Third Party. 

  

	 	1.8	Diagnostic Applications. “Diagnostic Applications” shall mean applications and any and all uses that if performed in the United States would require
clearance or approval by the U.S. Food and Drug Administration (FDA) through the premarket notification (510(k)) or premarket approval (PMA) process and any and all in vitro diagnostic applications and uses (including those exempt from FDA
premarket clearance or approval). 

  

	 	1.9	Field. “Field” shall mean all human Diagnostic Applications, excluding: (a) newborn screening and maternal/fetal prenatal testing, except for the
screening and/or testing of cystic fibrosis, and (b) nucleic acid or protein separation, fractionation and life science applications. 

  

	 	1.10	GAAP. “GAAP” shall mean United States generally accepted accounting principles, consistently applied. 

 

	 	1.11	Improvement Patents. “Improvement Patents” shall mean any and all Patent Rights Controlled by Licensor or its Affiliates relating to and within the
scope of Microfluidics Technology and that has been first conceived and reduced to practice by Licensor or its Affiliates after the Effective Date and during the Term of this Agreement. 

  
 2 

	 	1.12	Licensed Product. “Licensed Product” shall mean a product (a) Proprietary to Licensee and (b) the manufacture, use, sale, offer for sale or
importation of which would, but for the licenses granted herein, infringe a Valid Claim within the Licensed Patents. 

  

	 	1.13	Licensed Patents. “Licensed Patents” shall mean Patent Rights Controlled by Licensor as of the Effective Date of this Agreement that claim or relate to
Microfluidics Technology, including those listed in Exhibit A attached hereto; provided, however, that “Licensed Patents” shall not include intellectual property (a) licensed by Licensor from Monogram Biosciences, Inc., or
(b) directed to imaging chemistry, imaging automation and/or imaging instrumentation technologies. For clarity, “Licensed Patents” includes any patent that claims or relates to Microfluidics Technology issued following the Effective
Date from a patent application filed on or prior to the Effective Date or that claims priority to a patent or patent application filed on or before the Effective Date. 

 

	 	1.14	Microfluidics Technology. “Microfluidics Technology” shall mean compositions of matter, methods and other technology applicable to moving fluids
through, and/or modifying chemical and/or biochemical reactions within, channels or chambers, including methods for the manufacture or use of any Microfluidic Device and any devices or software used in connection with any Microfluidic Device.
“Microfluidics Technology” shall also include compositions of matter, methods and other technology relating to (a) the structure, design, and manufacture of such fluidics devices, (b) the interfacing of such fluidics devices to
external Instruments, (c) the control of fluid movement within, into, and out of such fluidics devices, (d) performing experiments and/or separations within such fluidics devices, (e) the detection of experimental results from or in
association with such fluidic devices, and (f) software relating to each of the foregoing. 

  

	 	1.15	Microfluidic Device. “Microfluidic Device” shall mean a consumable device comprising a microfluidic or mesofluidic channel(s).

  

	 	1.16	Net Sales. “Net Sales” shall mean: 

 the amount of revenue actually received by Licensee or its Affiliate(s), during any specified period in accordance with GAAP for the sale, transfer, or other disposition of a Licensed Product, less the
following deductions to the extent applicable to such amounts: (i) all trade, cash and quantity credits, discounts, rebates or refunds; (ii) credits or allowances for returns, billing errors, damaged, outdated or recalled Licensed
Products, in each case during such period; and (iii) packaging costs, handling fees, insurance and prepaid freight, sales taxes, duties and other governmental charges (including value-

  
 3 

 
added tax), but excluding what is commonly known as income taxes; provided that if a Licensed Product is so sold or otherwise transferred for a single price in the form of a Combination Product,
Net Sales shall be further calculated pursuant to Section 1.16(b) below; 
 Notwithstanding the foregoing, in the event
that, in any given Calendar Quarter, a Licensed Product is sold as part of a Combination Product, the amount of revenue received for such Licensed Product shall be calculated by multiplying the revenue received for such Combination Product by the
fraction A/(A+B) where “A” is the average revenue received for such Licensed Product(s) sold separately during such Calendar Quarter, and “B” is the average revenue received for the other items included in such Combination
Product sold separately during such Calendar Quarter. 
 In the event that such separate sales of components in a Combination
Product were not made or performed during the applicable Calendar Quarter, then the amount of revenue received for a Licensed Product that is sold as part of a Combination Product shall be calculated by multiplying the amount of revenue received for
the Combination Product by *** percent (***%). The parties agree that any allocation of revenue from the sale or other disposition of Combination Products pursuant to this Section 1.16(b) shall be done in good faith, and shall take into
consideration revenue recognition guidance under GAAP which is applicable to multiple-deliverable revenue arrangements. 
 Net
Sales shall not include sales between or among Licensee and its Affiliate; provided that if Licensee sells a Licensed Product to an Affiliate for resale, Net Sales shall include sales by such Affiliate in accordance with GAAP in connection with the
resale of such Licensed Product to a Third Party. 
 Notwithstanding anything else in this in this section, the supply or other
disposition of Licensed Products without charge as (i) samples, or (ii) for use in any tests or studies reasonably necessary to comply with any applicable law, regulation or request by a regulatory or governmental authority or as is
otherwise reasonable and customary in the industry, in each case shall not be included within the computation of Net Sales. 
  

	 	1.17	Patent Rights. “Patent Rights” shall mean any and all patents, patent applications, including any and all divisionals, continuations,
continuations-in-part, reissues, reexaminations, restorations (including supplemental protection certificates) and extensions, pipeline protection, invention certificates, and substitutions of any of the above. 

 

	 	1.18	Proprietary to Licensee. “Proprietary to Licensee” shall mean, with respect to any product, either: (a) Licensee owns, or exclusively or
co-exclusively licenses, a Patent Right that covers the making, using, selling, offering for 

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 4 

	 	
sale, or import of such product, or (b) the product embodies or incorporates any other property or intellectual property right owned by or exclusively or co-exclusively licensed to Licensee.
In the event of a Change of Control of Licensee, following such Change of Control the term “Proprietary to Licensee” shall be based on (a) the Patent Rights and/or (b) other such property or intellectual property right owned or
licensed or otherwise protected by Licensee as a trade secret that are in existence immediately prior to the consummation of such Change of Control transaction, and improvements thereto. 

 

	 	1.19	Royalty Term. “Royalty Term” shall mean the period of time beginning on the Effective Date and, on a Licensed Product-by-Licensed Product, and
country-by-country basis, extending until the date on which the last Valid Claim included within the Licensed Patents covering such Licensed Product in such country ceases to be a Valid Claim. 

 

	 	1.20	Territory. “Territory” shall mean the entire world. 

  

	 	1.21	Third Part(y/ies). “Third Part(y/ies)” shall mean any person(s) or entit(y/ies) other than Licensee, Licensor or their respective Affiliates.

  

	 	1.22	Valid Claim. “Valid Claim” shall mean an issued and unexpired claim of any United States or foreign Patent Right, which claims has not been donated to
the public, cancelled, withdrawn, abandonded, disclaimed, or revoked, or held invalid or unenforceable by a court or government agency of competent jurisdiction in an unappealed or unappealable decision. 

 

	2.	GRANT OF LICENSE 

  

	 	2.1	License to Licensed Patents. Subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee and its Affiliates a non-exclusive,
royalty-bearing license under the Licensed Patents to make, have made, use, import, export, offer for sale, sell and otherwise commercialize Licensed Products in the Territory in the Field. Under the license granted pursuant to this
Section 2.1, Licensee shall be permitted to authorize the use of the Licensed Products by its customers within the Field. The license rights granted to Licensee pursuant to this Section 2.1 shall not include any right to grant any
sublicenses under the Licensed Patents, except (i) as may be required to enable Licensee to distribute Licensed Products via an authorized distributor or other reseller, or (ii) as may be necessary for Licensee to have a Third Party
design, develop or manufacture Licensed Products in collaboration with or for Licensee. Licensed Products shall be sold only by Licensee, it Affiliates or authorized distributors or resellers. 

 

	 	2.2	 Option to Improvement Patents. Subject to the terms and conditions of this Agreement, Licensor grants to Licensee an option to obtain a
non-exclusive, royalty-bearing license under the Improvement Patents to make, 

  
 5 

	 	
have made, use, import, export, offer for sale, sell and otherwise commercialize Licensed Products in the Territory in the Field. Licensee may exercise this option at any time during the first
two (2) years of this Agreement by providing written notice to Licensor. If Licensee exercises its option to Improvement Patents, the Parties shall negotiate in good faith to determine the specific terms and conditions on which the license
shall be granted by Licensor to Licensee, in accordance with generally accepted industry standards. 

  

	 	2.3	No Implied Licenses. Nothing herein shall be construed as granting Licensee, by implication, estoppel or otherwise, any license or other right to any
intellectual property of Licensor other than the Licensed Patents or to grant to Licensee any right or license other than those expressly granted herein. 

  

	3.	CONSIDERATION. 

  

	 	3.1	Initial License Fee. Licensee shall pay to Licensor a license fee in the amount of *** United States Dollars ($***) in consideration for the license granted to
the Licensed Patents. This license fee shall be payable on or before March 31, 2012, and shall be fully earned by Licensor on the Effective Date. In the event that Licensee does not pay the license fee to Licensor as provided in this
Section 3.1, Licensee’s license rights under the Licensed Patents pursuant to this Agreement shall be terminated after written notice and Licensee’s failure to cure within thirty (30) days of such notice.

  

	 	3.2	Royalty Payments. During the Term of this Agreement, as additional consideration for the license and rights granted to Licensee pursuant to Section 2.1
above, for each Calendar Quarter (or portion thereof) during the Royalty Term, Licensee shall pay running royalties on Net Sales of Licensed Products to Licensor as follows: 

 

	 	(i)	***% of those Net Sales of Licensed Products during a particular Calendar Year between US$*** and US$***; 

 

	 	(ii)	***% of those Net Sales of Licensed Products during a particular Calendar Year between US$*** and US$***; and 

 

	 	(iii)	***% of those Net Sales of Licensed Products during a particular Calendar Year greater than US$***; 

For clarity, no royalty shall be due on Net Sales of Licensed Products in any Calendar Year less than $***. 

In order to calculate the running royalty payment to be paid for each Calendar Quarter, aggregate Net Sales of Licensed Products
occurring 
  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 6 

 
between the start of the applicable Calendar Year in which the Calendar Quarter falls to the end of that Calendar Quarter, and the associated royalty rate tiers achieved and surpassed, shall be
used. 
  

	 	3.3	Royalty Stacking. If Licensee or an Affiliate has obtained or obtains a license(s) from Third Party(ies) for Microfluidics Technology that Licensees reasonably
believes is necessary or useful to make, have made, use, sell, offer for sale or import any Licensed Product, Licensee may deduct or credit *** percent (***%) of any royalties payable to such Third Party(ies) from or against running royalties due to
Licensor pursuant to this Agreement, provided that in no event shall the running royalties paid to Licensor be reduced by more than *** percent (***%) of the royalties otherwise owed to Licensor absent such deduction or credit. In the event that
Licensee claims the benefit of the provisions of this Section 3.3, Licensee shall provide Licensor with reasonable evidence, for example, evidence from a license agreement or royalty report, supporting the amounts deducted or credited against
royalties due to Licensor. Licensee’s obligation to provide any such evidence shall be subject to any obligation of Licensee to a Third Party restricting or preventing the disclosure of such information. All information of Licensee which is
provided to Licensor under this Section 3.3 shall be deemed to be Licensee’s Confidential Information subject to the provisions of Article 5 hereof. 

 

	 	3.4	Single Royalty. Notwithstanding anything herein to the contrary, with respect to any Licensed Product for which a royalty payment is due only a single royalty
payment shall be due and payable, regardless if such Licensed Product is covered by more than one Valid Claim. 

  

	 	3.5	Milestone Payments. As additional consideration for the rights granted to Licensee pursuant to Section 2.1 above, Licensee shall also pay to Licensor the
following one-time milestone payments, each distinct and not subsumed by another: 

  

	 	(a)	$*** no later than thirty (30) days after the end of the first Calendar Year in which cumulative Net Sales of Licensed Products following the Effective Date first
exceed $***;. 

  

	 	(b)	$*** no later than thirty (30) days after the end of the first Calendar Year in which cumulative Net Sales of Licensed Products following the Effective Date first
exceed $***; 

  

	 	(c)	$*** no later than thirty (30) days after the end of the first Calendar Year in which cumulative Net Sales of Licensed Products following the Effective Date first
exceed $***; and 

  

	 	(d)	$*** no later than thirty (30) days after a Change of Control of Licensee. 

 

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 7 

	 	3.6	Royalty Statements and Payments. Licensee, within forty five (45) days after the end of each Calendar Quarter, shall deliver to Licensor a report setting
forth for such Calendar Quarter the following information, on a Licensed-Product-by-Licensed-Product basis: (a) the Net Sales of each Licensed Product, (b) the cumulative Net Sales of Licensed Products occurring since the start of the
applicable Calendar Year and since the Effective Date, and (c) the royalties due hereunder for such Net Sales of each Licensed Product. The total running royalty due for the sale or other disposition of Licensed Products during such Calendar
Quarter shall be remitted at the time such report is made. Any royalties not paid when due in accordance with this Section 3.6 accrue interest from the date due at the “bank prime loan” rate (as defined in the U.S. Federal Reserve
Bulletin H.15 or any successor thereto) on the last business day of the applicable Calendar Quarter prior to the date on which such payment is due, plus *** percent (***%) per annum, calculated on the basis of a 360-day year.

  

	 	(a)	Taxes and Withholding. All payments under this Agreement will be made without any deduction or withholding for or on account of any tax unless such deduction or
withholding is required by applicable laws or regulations. If Licensee is so required to deduct or withhold, Licensee will (i) promptly notify Licensor of such requirement, and (ii) upon request, promptly forward to Licensor an official
receipt (or certified copy) or other available documentation evidencing such payment to such authorities. 

  

	 	(b)	Currency. All amounts payable and calculations hereunder shall be in United States dollars. As applicable, Net Sales and any deductions therefrom shall be
translated into United States dollars at the daily 12 noon buying rate certified by the New York Federal Reserve Bank on the last date of the applicable Calendar Quarter. 

 

	 	(c)	Blocked Currency. If at any time legal restrictions prevent the prompt remittance of part or all of payments owed by Licensee with respect to any country in the
Territory where Licensed Products are sold, royalty payments on Net Sales of Licensed Products due hereunder shall continue to accrue, and shall continue to be reported, until such time payment shall be made through any lawful means or methods that
may be available as Licensee shall reasonably determine. 

  

	 	3.7	Maintenance of Records; Audits. 

  

	 	(a)	Record Keeping. Licensee shall keep, and shall cause its Affiliates to keep, accurate books and accounts of record in connection with the sale of Licensed
Products, in sufficient detail to permit accurate determination and verification of the running royalties to be paid hereunder. Licensee and its Affiliates shall maintain such records for a period of at least three (3) years after the end of
the Calendar Year to which they pertain. 

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 8 

	 	(b)	Audits. Upon not less than thirty (30) days prior written notice from Licensor, Licensee shall permit an independent certified public accounting firm
selected by Licensor and reasonably acceptable to Licensee, to examine, at Licensor’s sole expense, the relevant books and records of Licensee and its Affiliates necessary to verify the accuracy of the reports submitted by Licensee in
accordance with Section 3.6 and the payment of royalties hereunder. An examination by Licensor under this Section 3.6 shall occur not more than once in any Calendar Year and shall be limited to the pertinent books and records for any
Calendar Year ending not more than three (3) years before the date of the request, and shall not be permitted more than once with respect to records covering any specific period of time. The accounting firm shall be provided access to such
books and records at Licensee’s facility(ies) where such books and records are normally kept and such examination shall be conducted during Licensee’s normal business hours upon reasonable advance notice by Licensor solely to verify the
accuracy of the reports submitted by Licensee in accordance with Section 3.6 and the payment of royalties hereunder; provided that such independent certified public accounting firm has entered into a written agreement with Licensee limiting the
use of such records to verification of the accuracy of royalties due under this Agreement and prohibiting the disclosure of any information contained in such records to a Third Party for any purpose and to Licensor for a purpose other than as set
forth in this Section. Upon completion of the audit, the accounting firm shall provide both Licensee and Licensor with a written report including a numerical summary of payments due and paid, and a description of the basis for any discrepancy
therebetween. 

  

	 	(c)	Underpayments. If the accounting firm retained pursuant to Section 3.7(b) concludes that additional running royalties were due to Licensor, Licensee shall
pay to Licensor the additional running royalties within thirty (30) days of the date Licensee receives such accountant’s written report so concluding. Any overpayment made by Licensee shall be fully creditable against amounts payable in
subsequent payment periods. If the accountant’s written report concludes that Licensee made an overpayment, but the Royalty Term of the Agreement has expired, Licensor shall refund the uncontested portion of the overpayment to Licensee within
thirty (30) days of the date Licensor receives such accountant’s written report. If Licensee has underpaid royalties due to Licensor hereunder by more than seven and one-half percent (7.5%), then, provided the audited period includes at
least four (4) consecutive Calendar Quarters, Licensee shall pay the reasonable expenses of the accounting firm retained pursuant to this Section 3.7. 

  
 9 

	 	(d)	Confidentiality. All financial information of Licensee which is subject to review under this Section 3.6 shall be deemed to be Licensee’s Confidential
Information subject to the provisions of Article 5 hereof. 

  

	 	3.8	Form of Payments. Unless otherwise mutually agreed in writing, any and all payments to Licensor required under this Agreement shall be made by wire transfer to:

 *** 
  

	4.	INTELLECTUAL PROPERTY. 

  

	 	4.1	Filing, Prosecution and Maintenance of Licensed Patents. Licensor, at its own expense, shall have the sole right to prepare, file, prosecute and maintain,
throughout the world, all of the Licensed Patents. Upon Licensee’s written request, Licensor shall provide Licensee with information regarding the current status of any Patent Rights included in the Licensed Patents, and any related
documentation. Nothing in this Agreement shall be deemed to limit Licensor’s ability to abandon any of the Licensed Patents. 

  

	5.	CONFIDENTIALITY. 

  

	 	5.1	Confidentiality. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that, for the term of this
Agreement and for five (5) years thereafter, each Party (the “Receiving Party”) receiving any Confidential Information of the other Party (the “Disclosing Party”) hereunder shall keep such Confidential
Information confidential and shall not publish or otherwise disclose or use such Confidential Information for any purpose other than as provided for in this Agreement, except for Confidential Information that the Receiving Party can establish:

  

	 	(a)	was already known by the Receiving Party (other than under an obligation of confidentiality) at the time of disclosure by the Disclosing Party;

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 10 

	 	(b)	was available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party; 

 

	 	(c)	became available to the public or otherwise part of the public domain after its disclosure to the Receiving Party other than through any act or omission of a Party in
breach of this Agreement; 

  

	 	(d)	was disclosed to the Receiving Party by a Third Party who had no obligation to the Disclosing Party not to disclose such information to others; or

  

	 	(e)	was independently discovered or developed by or on behalf of the Receiving Party without the use of the Confidential Information. 

Notwithstanding the foregoing, each Party may disclose the other Party’s Confidential Information and the terms of this Agreement to
its advisors, consultants, investors and potential acquirers who have a need to know such Confidential Information and are bound by obligations of confidentiality and non-use substantially similar to those set forth herein. 

 

	 	5.2	Authorized Disclosure. Notwithstanding the foregoing Section 5.1, each Party may disclose Confidential Information belonging to the other Party to the
extent such disclosure is reasonably necessary to: 

  

	 	(a)	exercise rights hereunder provided such disclosure is covered by terms of confidentiality similar to those set forth herein, or 

 

	 	(b)	comply with applicable governmental laws and regulations. 

 In the event the Receiving Party shall deem it necessary to disclose Confidential Information pursuant to this Section 5.2(b), the Receiving Party shall, to the extent possible, give reasonable
advance notice of such disclosure to the Disclosing Party and provide reasonable assistance to allow the Disclosing Party to seek confidential treatment of such information. 

 

	 	5.3	SEC Filings. Notwithstanding Section 5.2, Either Party may disclose the terms of this Agreement to the extent required, in the reasonable opinion of such
Party’s legal counsel, to comply with applicable laws, including, without limitation, the rules and regulations promulgated by the United States Securities and Exchange Commission. Before disclosing this Agreement or any of the terms hereof
pursuant to this Section 5.3, the Parties will consult with one another on the terms of this Agreement to be redacted in making any such disclosure. 

  

	 	5.4	Public Announcements. Except as may be expressly permitted under Section 5.3, neither party will make any public announcement regarding this Agreement
without the prior written approval of the other Party. 

  
 11 

	6.	REPRESENTATIONS AND WARRANTIES. 

  

	 	6.1	Representations and Warranties of Each Party. Each of Licensor and Licensee hereby represents and warrants to the other Party as follows:

  

	 	(a)	it is a corporation or entity duly organized and validly existing under the laws of the state or other jurisdiction of its incorporation or formation;

  

	 	(b)	the execution, delivery and performance of this Agreement by such Party has been duly authorized by all requisite corporate action; 

 

	 	(c)	it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder on behalf of itself and its Affiliates as of the Effective
Date of this Agreement; 

  

	 	(d)	the execution, delivery and performance by such Party of this Agreement and its compliance with the terms and provisions hereof does not and will not conflict with or
result in a breach of any of the terms and provisions of or constitute a default under (i) any agreement or instrument binding or affecting it or its property; (ii) the provisions of its charter or operative documents or bylaws; or
(iii) any order, writ, injunction or decree of any court or governmental authority entered against it or by which any of its property is bound; and 

  

	 	(e)	the person executing this Agreement has all power and authority necessary to do so. 

 

	 	6.2	Disclaimer. EXCEPT AS PROVIDED IN THIS ARTICLE 6, NEITHER PARTY MAKES ANY WARRANTIES OR CONDITIONS (EXPRESS, IMPLIED, STATUTORY OR OTHERWISE) WITH RESPECT TO THE
SUBJECT MATTER HEREOF, AND LICENSOR SPECIFICALLY DISCLAIMS ANY AND ALL IMPLIED WARRANTIES OR CONDITIONS OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, AND ALL WARRANTIES AND CONDITIONS OF THE VALIDITY OF THE LICENSED PATENTS OR
NONINFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS. 

  

	 	6.3	Representation by Legal Counsel. Each Party hereto represents that it has been represented by legal counsel in connection with this Agreement and acknowledges
that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption shall exist or be implied against the party which drafted such terms and provisions.

  
 12 

	 	6.4	Indemnity. Licensee shall indemnify, defend and hold harmless Licensor and its respective officers, employees, and agents, and their respective successors and
assigns (the “Indemnitees”) against any third party liability, damage, loss or expense (including reasonable attorney’s fees and expenses of litigation) incurred by or imposed upon the Indemnitees or any one of them in connection with
any claim, suit, action, demand or judgment arising directly out of Licensee, its Affiliates or authorized distributors or resellsers’ manufacture, use, sale, offer for sale or import of Licensed Products. Licensee’s indemnification shall
not apply to any liability, damage, loss or expense to the extent that it is attributable to the acts or omissions of the Indemnitees. The foregoing obligation of indemnity is subject to the condition that the Indemnitee shall promptly notify
Licensee on being notified or otherwise made aware of a liability, claim, suit, action, demand or judgment and that Licensee defend and control any proceedings using counsel of its choice (with Licensor being permitted to participate at its own
expense); provided, that, an Indemnitee may not settle any liability, claim, suit, action, demand or judgment, or otherwise consent to any judgment, without the written consent of Licensee. 

 

	 	6.5	No Other Microfluidics Patent Rights. Licensor represents and warrants that, as of the Effective Date, there are no Patent Rights Controlled by it or its
Affiliates, other than the Licensed Patents, that claim or relate to compositions of matter, methods and other technology applicable to moving fluids through, and/or modifying chemical and/or biochemical reactions within, meso or micro scale
channels or chambers, including methods for the manufacture or use of any consumable devices comprising such channels or chambers and any devices or software used in connection therewith (including any compositions of matter, methods and other
technology relating to (a) the structure, design, and manufacture of such fluidics devices, (b) the interfacing of such fluidics devices to external Instruments, (c) the control of fluid movement within, into, and out of such fluidics
devices, (d) performing experiments and/or separations within such fluidics devices, (e) the detection of experimental results from or in association with such fluidic devices, and (f) software relating to each of the foregoing).

  

	7.	TERM AND TERMINATION. 

  

	 	7.1	Term. The term of this Agreement will commence on the Effective Date and extend in perpetuity, unless this Agreement is terminated earlier in accordance with
this Article 7, on a Licensed-Product-by-Licensed-Product, and country-by-country basis until such time as the Royalty Term with respect to the sale of such Licensed Product in such country expires. 

 

	 	7.2	 Termination for Breach. This Agreement may be terminated effective immediately by written notice by either Party at any time during the term of
this Agreement for material breach by the other Party, which breach remains 

  
 13 

	 	
uncured for sixty (60) days, measured from the date written notice of such breach is given to the breaching Party; provided, however, that if such breach is not susceptible of cure within
such sixty (60) day period and the breaching Party uses diligent good faith efforts to cure such breach, such period will be extended as reasonably necessary to cure such breach. However, if Licensee is alleged to be in breach of Article 3 of
this Agreement, and Licensee disputes in good faith such breach by written notice to Licensor within such sixty (60) day period (which notice shall set forth in reasonable detail the basis for Licensee’s belief that it is not in default
under this Agreement), Licensor shall not have the right to terminate this Agreement until (a) it has been determined through the dispute resolution process provided in Section 9.2 of this Agreement, that Licensee has materially breached
Article 3 of this Agreement, and (b) Licensee fails, within thirty (30) days after such determination, to pay, if any, all accrued and unpaid royalties due under this Agreement, together with interest in accordance with Article 3.

  

	 	7.3	Bankruptcy. 

  

	 	(a)	Termination Upon a Bankruptcy Event. To the extent permitted by applicable law, each Party shall have the right to terminate this Agreement upon written notice
to the other party in the event of a Bankruptcy Event with respect to the other Party. “Bankruptcy Event” means the occurrence of any of the following: (a) the institution of any bankruptcy, receivership, insolvency,
reorganization or other similar proceedings by or against a party under any bankruptcy, insolvency, or other similar law now or hereinafter in effect, including any section or chapter of the U.S. Bankruptcy Code, as amended or under any similar laws
or statutes of the United States or any state thereof, where in the case of involuntary proceedings such proceedings have not been dismissed or discharged within one hundred (120) days after they are instituted, (b) the making of an
assignment for the benefit of creditors as to all or substantially all of a party’s assets, or (c) the appointment of a receiver, custodian, trustee, liquidator, assignee or other similar official for all or substantially all of a
party’s assets. 

  

	 	(b)	Rights under Bankruptcy Code. All rights and licenses granted under or pursuant to this Agreement by Licensor are, and shall otherwise be deemed to be, for
purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code. The parties agree that Licensee, as licensee of intellectual property
under this Agreement, shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. 

  
 14 

	 	7.4	Termination by Licensee. Licensee shall have the right, exercisable upon thirty (30) days prior written notice to Licensor, to terminate this Agreement.

  

	 	7.5	Termination by Licensor. Licensor shall have the right to terminate this Agreement if Licensee or an Affiliate of Licensee, after the Effective Date, institutes
a suit, reexamination, nullity action, opposition to grant, or other legal action in that country, seeking to invalidate the claims of a Licensed Patent, or if Licensee or an Affiliate of Licensee actively participates (other than by legal
compulsion) in any of the foregoing (a “Patent Challenge”), except if such Patent Challenge is in whole or part made in defense of a suit or other action against or threatened against Licensee or any of its Affiliates. Such
termination shall be effective thirty (30) days after written notice by Licensor to Licensee, unless, within such thirty (30) days, Licensee (or its applicable Affiliate) withdraws such Patent Challenge; provided, however, that if any
delay in such withdrawal is caused by an act or omission by Licensor or any of its Affiliates, such 30-day period shall be extended for a period of time equal to the amount of delay caused by Licensor or its Affiliate. 

 

	 	7.6	Effects of Termination. Upon termination of this Agreement for any reason other than a material, uncured breach by Licensor, all licenses granted by Licensor to
Licensee hereunder will automatically terminate and be of no further force and effect; provided, however, that Licensee shall have the rights for a reasonable period of time, not to exceed six (6) months, to dispose of existing inventory of
Licensed Products, and further provided that all provisions relating to earned royalty obligations set forth herein shall survive termination as to any Licensed Products sold after the effective date of termination. 

 

	 	7.7	Survival of Certain Obligations. Expiration or termination of the Agreement shall not relieve the Parties of any obligation accruing before such expiration or
termination, and the applicable provisions of Article 1, 5 and 8, and Sections 3.7, this Section 7.7, Section 9.7 and Section 9.10 shall survive the expiration or termination of the Agreement. Any expiration or early termination of
this Agreement shall be without prejudice to the rights of either Party against the other accrued or accruing under this Agreement before termination, including, without limitation, the obligations to pay royalties for Licensed Products sold before
such termination. 

  

	8.	RELEASE. 

  

	 	8.1	 Release by Licensor. Licensor, on behalf of itself, and its predecessors, successors and assigns, and any parents, subsidiaries and Affiliates,
does hereby now and forever release and discharge Licensee, and its predecessors, successors and assigns, and any parents, subsidiaries and other Affiliates, 

  
 15 

	 	
and each of their respective current and former officers, directors, employees, agents, attorneys, and representatives (individually and collectively, the “Released Parties”)
from any and all known or unknown claims, damages, actions, causes of actions, defenses, demands, costs or charges, in law or equity, based upon any Released Parties’ manufacture, use, marketing, sale, offering for sale, import or distribution
of Licensed Products on or prior to the Effective Date. 

  

	 	8.2	Waiver Of California Civil Code Section 1542 With Respect To The Released Claims. Each Party acknowledges familiarity with the provisions of
Section 1542 of the California Civil Code and expressly waives and releases any rights or benefits arising thereunder. Section 1542 of the California Civil Code states: 

“A general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of
executing the release, which if known by him must have materially affected his settlement with the debtor.” 
  

	9.	MISCELLANEOUS. 

  

	 	9.1	Assignment. Neither this Agreement nor any interest hereunder shall be assignable by Licensee, without the prior written consent of Licensor, which consent shall
not be unreasonably withheld or delayed. Notwithstanding the foregoing, Licensor may freely assign this Agreement to an Affiliate or in connection with the sale of all or substantially all of its assets, to which this Agreement pertains, and
Licensee may freely assign this Agreement in connection with a Change of Control provided that the provisions of Section 3.4(d) have been complied with. This Agreement shall be binding upon the successors and permitted assigns of the Parties
and the name of a Party appearing herein shall be deemed to include the names of such Party’s successors and permitted assigns to the extent necessary to carry out the intent of this Agreement. Any assignment not in accordance with this
Section 9.1 shall be void. 

  

	 	9.2	Dispute Resolution. Except as set forth below, Any disputes under this Agreement shall be determined in a dispute resolution process as outlined in this
Section 9.2. 

  

	 	(a)	 Senior Management Consultation. Each Party agrees that, as a first step in any dispute resolution, it shall give the other Party written notice
of its grievance and request and participate in a meeting with a senior executive of the other Party to discuss the matter in order to consider informal and amicable means of resolution, and refrain from

  
 16 

	 	
formal dispute resolution for a period of thirty (30) days after such notice to allow for such a meeting (such time being extendable for good cause by mutual agreement).

  

	 	(b)	Binding Arbitration. If the Parties are unable to resolve their dispute informally through senior management consultation, as contemplated by this
Section 9.2., then either Party may demand binding arbitration before JAMS, using the then current JAMS comprehensive arbitration rules and procedures, in which arbitration the following procedures shall control: 

 

	 	(i)	The dispute shall be submitted to a single JAMS arbitrator for resolution. 

 

	 	(ii)	If possible, the arbitrator shall be selected jointly by the Parties. If the Parties are unable to agree, an arbitrator shall be selected in accordance with the rules
and procedures of JAMS. 

  

	 	(iii)	Each Party shall be entitled to submit to the other party one set of document requests and one set of simple interrogatories numbering no more than twenty (20), and to
take no more than five (5) depositions lasting no more than twenty (20) hours in the aggregate. 

  

	 	(iv)	After exchange and submission of briefs by each Party, each main brief not to exceed twenty five (25) pages and reply brief ten (10) pages, each Party shall
have a total of two hours in which to argue its case to the arbitrator, unless the arbitrator believes that a decision on the briefs is preferable which shall be entirely his or her decision. All evidence shall be submitted by declaration under
oath. There will be no live testimony at the hearing. 

  

	 	(v)	A decision shall be rendered by the arbitrator in writing within thirty (30) days of the submission of the dispute by the parties to the arbitrator for resolution,
which decision shall be final and binding on the Parties. 

  

	 	(vi)	The arbitrator shall have no power to award any relief other than injunctive relief and monetary relief for damages actually incurred, and appropriate declaratory
relief with respect to disputed issues under, in connection with, or arising out of this Agreement. 

  

	 	(vii)	The Parties shall bear their own attorneys fees and costs of the arbitration, except that the arbitrator may, in his or her discretion, award attorneys’ fees and
costs to the prevailing Party, or a portion thereof, upon a finding that the non-prevailing party acted in bad faith. 

  
 17 

	 	(viii)	If the winning Party does not receive the full amount and benefit of the arbitration result from the losing party within thirty (30) days of the decision, the
winning Party may resort to the courts of the Commonwealth of Massachusetts to obtain a Court order against the losing Party, and the losing Party shall bear all the costs of the winning Party in such procedure. 

Notwithstanding foregoing, any dispute not resolved internally by the Parties pursuant to Section 9.2(a) that involves the validity,
infringement or enforceability of a Licensed Patent (a) that is issued in the United States shall be subject to actions before the United States Patent and Trademark Office and/or submitted exclusively to the federal court located in the
jurisdiction of the district where any of the defendants reside; and (b) that is issued in any other country (or region) shall be brought before an appropriate regulatory or administrative body or court in that country (or region), and the
Parties hereby consent to the jurisdiction and venue of such courts and bodies. 
  

	 	9.3	Force Majeure. Neither Party shall be liable to the other for delay or failure in the performance of the obligations on its part contained in this Agreement if
and to the extent that such failure or delay is due to circumstances beyond its control which it could not have avoided by the exercise of reasonable diligence. It shall notify the other Party as soon as reasonably possible should such circumstances
arise, giving an indication of the likely extent and duration thereof, and shall use all reasonable efforts to resume performance of its obligations as soon as practicable; provided, however, that neither Party shall be required by this
Section 9.3 to settle any labor dispute or disturbance. 

  

	 	9.4	Correspondence and Notices. Any notices required hereunder shall be in writing and shall be deemed given if delivered personally or by facsimile transmission
(receipt verified), mailed by registered or certified mail (return receipt requested), postage prepaid, or sent by nationally recognized express courier service, to the Parties at the following addresses (or at such other address for a Party as
shall be specified by like notice; provided, however, that notices of a change of address shall be effective only upon receipt thereof). 

 All correspondence to Licensee shall be addressed as follows: 
 GenMark
Diagnostics, Inc., 
 5964 La Place Court 
 Carlsbad, CA 92008 

  
 18 

 Attn: Corporate Secretary 

Fax: (760) 448-4301 
 All correspondence to Licensor shall be addressed as follows: 
 Caliper Life
Sciences Corporation 
 68 Elm Street 
 Hopkinton, MA 01748 
 Attn: Asst. General Counsel 

Fax: (774) 278-2726 
 with a copy to: 
 PerkinElmer Health Sciences, Inc. 

940 Winter Street 
 Waltham, MA 02451 
 Attn: General Counsel 

Fax: (781) 663-5970 
  

	 	9.5	Amendment. No amendment, modification or supplement of any provision of this Agreement shall be valid or effective unless made in writing and signed by a duly
authorized officer of each Party. 

  

	 	9.6	Waiver. No provision of this Agreement shall be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing
expressly waiving such provision and signed by a duly authorized officer of the waiving Party. 

  

	 	9.7	Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ANY THIRD PARTY FOR ANY SPECIAL, CONSEQUENTIAL, EXEMPLARY OR INCIDENTAL DAMAGES
(INCLUDING LOST OR ANTICIPATED REVENUES OR PROFITS RELATING TO THE SAME), ARISING FROM ANY CLAIM RELATING TO THIS AGREEMENT, WHETHER SUCH CLAIM IS BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, EVEN IF AN AUTHORIZED REPRESENTATIVE OF
SUCH PARTY IS ADVISED OF THE POSSIBILITY OR LIKELIHOOD OF SAME. 

  

	 	9.8	Severability. If any clause or portion thereof in this Agreement is for any reason held to be invalid, illegal or unenforceable, the same shall not affect any
other portion of this Agreement, as it is the intent of the Parties that this Agreement shall be construed in such fashion as to maintain its existence, validity and enforceability to the greatest extent possible. In any such event, this Agreement
shall be construed as if such clause of portion thereof had never been contained in this Agreement, and there shall be deemed substituted therefor such provision as will most nearly carry out the intent of the Parties as expressed in this Agreement
to the fullest extent permitted by applicable law. 

  
 19 

	 	9.9	Interpretation. The descriptive headings of this Agreement are for convenience only, and shall be of no force or effect in construing or interpreting any of the
provisions of this Agreement. In this Agreement, the singular shall include the plural and vice versa and the word “including” shall be deemed to be followed by the phrase “without limitation.” 

 

	 	9.10	Governing Law. This Agreement shall be governed by and interpreted in accordance with the substantive laws of the Delaware, without regard to conflict of law
principles thereof. 

  

	 	9.11	Entire Agreement of the Parties. This Agreement constitutes and contains the complete, final and exclusive understanding and agreement of the Parties and cancels
and supersedes any and all prior negotiations, correspondence, understandings and agreements, whether oral or written, among the Parties respecting the subject matter hereof and thereof. 

 

	 	9.12	Independent Contractors. Both Parties are independent contractors under this Agreement. Nothing herein contained shall be deemed to create an employment, agency,
joint venture or partnership or fiduciary relationship between the parties hereto or any of their agents or employees, or any other legal arrangement that would impose liability upon one Party for the act or failure to act of the other Party.
Neither Party shall have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever.

  

	 	9.13	Counterparts. This Agreement may be executed in any number of counterparts, each of which need not contain the signature of more than one party but all such
counterparts taken together shall constitute one and the same agreement. Execution and delivery may be evidenced by a facsimile or electronic transmission of a signed copy of this Agreement. 

[Signature Page Follows] 

  
 20 

 IN WITNESS WHEREOF, duly authorized representatives of the parties have duly executed
this Agreement to be effective as of the Effective Date. 
  

									
	CLINCAL MICRO SENSORS, INC. 	 		 	CALIPER LIFE SCIENCES CORPORATION
					
	By	 	 /s/ Hany Massarany
	 		 	By	 	 /s/ Alan Fletcher

							
	Name:	 	Hany Massarany	 	   Name:	 	Alan Fletcher
	Title:	 	President and CEO	 	   Title:	 	VP & GM, New Markets

  
 21 

 EXHIBIT A 

LICENSED PATENTS 
 Exhibit A: Licensed Patents 
 Confidential 

 

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CIP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	DE	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CIP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CH	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CN	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 2 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	DE	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	JP	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	EDV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	JP	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	KR	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 3 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CN	  	DIV	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CIP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CH	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 4 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	FR	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	JP	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	RCE	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CH	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 5 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	GB	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	RCE	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 6 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 7 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	EP	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CIP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CN	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 8 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 9 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	CH	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CN	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	JP	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CIP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	JP	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	RCE	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 10 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 11 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	EP	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	JP	  	CIP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	PCT	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	EP	  	EPP	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 12 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CIP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 13 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	RCE	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	RCE	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 14 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 15 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 16 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	RCE	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CIP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	ORD	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 17 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	DIV	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	CON	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 18 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	JP	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	ORD	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 19 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	GB	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	RCE	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CN	  	CIP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 20 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	EP	  	PCT	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	CON	  	Allowed	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	EP	  	DIV	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 21 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	JP	  	DIV	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	CIP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CIP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 22 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	EP	  	DIV	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CIP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 23 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CIP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CH	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 24 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	EP	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	EPP	  	Allowed	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 25 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	CON	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CN	  	CIP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	JP	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	DIV	  	Allowed	  	CLS	  	***	  	***	  	***	  		  	

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 26 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	EP	  	DIV	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	RCE	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 27 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 28 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	EP	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	JP	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	CIP	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 29 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CN	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	MX	  	CIP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 30 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	JP	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	EDV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 31 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS &
 AGIL
	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CIP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 32 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	EP	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 33 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	EP	  	ORD	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CH	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 34 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	GB	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	CON	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CH	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CN	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	IN	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 35 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CIP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	CON	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 36 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	FR	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	JP	  	PCT	  	Allowed	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CH	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 37 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	DE	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	CIP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 38 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	PCT	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CN	  	CIP	  	Pending	  	CLS &
CANON	  	***	  	***	  	***	  		  	
										
	 ***
	  	EP	  	ORD	  	Pending	  	CLS &
CANON	  	***	  	***	  	***	  		  	
										
	 ***
	  	IN	  	ORD	  	Pending	  	CLS &
CANON	  	***	  	***	  	***	  		  	
										
	 ***
	  	JP	  	CIP	  	Pending	  	CLS &
CANON	  	***	  	***	  	***	  		  	

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 39 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	ORD	  	Pending	  	CLS &
CANON	  	***	  	***	  	***	  		  	
										
	 ***
	  	WO	  	ORD	  	Pending	  	CLS &
CANON	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 40 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	EP	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	CON	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	CIP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 41 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	FR	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CTC	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CH	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 42 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	EP	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 43 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CIP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	JP	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	ORD	  	Allowed	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	JP	  	DIV	  	Allowed	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 44 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	EP	  	PCT	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	EP	  	PCT	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CH	  	EPP	  	Granted	  	CLS &
WAKO	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 45 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	DE	  	EPP	  	Granted	  	CLS &
WAKO	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	EPP	  	Granted	  	CLS &
WAKO	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	ES	  	PCT	  	Granted	  	CLS &
WAKO	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	ORD	  	Granted	  	CLS &
WAKO	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	ORD	  	Granted	  	CLS &
WAKO	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	IT	  	EPP	  	Granted	  	CLS &
WAKO	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	JP	  	PCT	  	Granted	  	CLS &
WAKO	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	PCT	  	Pending	  	CLS &
WAKO	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	DIV	  	Allowed	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	JP	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 46 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	JP	  	EPP	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	EPP	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	CH	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 47 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	JP	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CN	  	PCT	  	Granted	  	CLS &
WAKO	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	KR	  	PCT	  	Granted	  	CLS &
WAKO	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	IN	  	PCT	  	Pending	  	CLS &
WAKO	  	***	  	***	  	***	  		  	
										
	 ***
	  	RU	  	PCT	  	Pending	  	CLS &
WAKO	  	***	  	***	  	***	  		  	
										
	 ***
	  	KR	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 48 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	JP	  	PCT	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	CN	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	DIV	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	KR	  	DIV	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	KR	  	EPC	  	Pending	  	CLS &
WAKO	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	EPC	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 49 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	JP	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CIP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CIP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 50 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	JP	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	EPP	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CN	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	ORD	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	EPP	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	EP	  	ORD	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	ORD	  	Pending	  	CLS	  	***	  	***	  	***	  		  	

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 51 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	ORD	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CN	  	PCT	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	JP	  	PCT	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	EP	  	PCT	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	WO	  	ORD	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	EP	  	DIV	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	PCT	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	JP	  	PCT	  	Allowed	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	ORD	  	Granted	  	CLS	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 52 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	DIV	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	PCT	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	WO	  	ORD	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	ORD	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	CIP	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	WO	  	PCT	  	Pending	  	CLS & FWC	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	PCT	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	EP	  	PCT	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	JP	  	PCT	  	Pending	  	CLS	  	***	  	***	  	***	  		  	

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 53 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	ORD	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	CIP	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	CIP	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	WO	  	ORD	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	WO	  	CIP	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	ORD	  	Pending	  	CLS	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	ORD	  	Pending	  	CLS	  	***	  	***	  	***	  		  	

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 54 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	CA	  	PCT	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CH	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	JP	  	ORD	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	HK	  	PIP	  	Opposed	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 55 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	ORD	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CIP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CA	  	PCT	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CH	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	HK	  	EPC	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 56 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	IT	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	JP	  	PCT	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	FWC	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	AT	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CA	  	PCT	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CH	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CN	  	PCT	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	IT	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	JP	  	PCT	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 57 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	MX	  	PCT	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	NL	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	SE	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CIP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	JP	  	DIV	  	Pending	  	PENN	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	RCE	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CA	  	PCT	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CH	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 58 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	EP	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	JP	  	PCT	  	Pending	  	PENN	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	FWC	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CA	  	PCT	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CH	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	IT	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	JP	  	PCT	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 59 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	FWC	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CA	  	PCT	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CH	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CN	  	PCT	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 60 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	EP	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	EPP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	JP	  	PCT	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CIP	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	MX	  	PCT	  	Pending	  	PENN	  	***	  	***	  	***	  		  	
										
	 ***
	  	US	  	DIV	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 61 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	CON	  	Granted	  	PENN	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	AT	  	EPP	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	BE	  	EPP	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CA	  	PCT	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CH	  	EPP	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CN	  	PCT	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 62 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	DE	  	EPP	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DK	  	EPP	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	EPP	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	ES	  	EPP	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	FR	  	EPP	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	GB	  	EPP	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	IE	  	EPP	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 63 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	DE	  	EPP	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	IT	  	EPP	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	JP	  	PCT	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	
										
	 ***
	  	KR	  	PCT	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	LU	  	EPP	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	MC	  	EPP	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	MX	  	PCT	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	NL	  	EPP	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 64 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	SE	  	EPP	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	DE	  	EDV	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	
										
	 ***
	  	EP	  	EDV	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	
										
	 ***
	  	US	  	CON	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	EP	  	EDV	  	Published	  	ORNL	  	***	  	***	  	***	  		  	

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 65 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	CON	  	Granted	  	ORNL	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	LOCK	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	RCE	  	Granted	  	LOCK	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	LOCK	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CIP	  	Granted	  	LOCK	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CA	  	PCT	  	Pending	  	LOCK	  	***	  	***	  	***	  		  	

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 66 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	JP	  	PCT	  	Pending	  	LOCK	  	***	  	***	  	***	  		  	
										
	 ***
	  	EP	  	EPP	  	Granted	  	LOCK	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	LOCK	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	DIV	  	Granted	  	LOCK	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	LOCK	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CA	  	PCT	  	Granted	  	LOCK	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 67 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	EP	  	EPP	  	Granted	  	LOCK	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	JP	  	PCT	  	Granted	  	LOCK	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CIP	  	Granted	  	LOCK	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	LOCK	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	CA	  	PCT	  	Pending	  	LOCK	  	***	  	***	  	***	  		  	
										
	 ***
	  	EP	  	EPP	  	Grantede	  	LOCK	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 68 

 Exhibit A: Licensed Patents 

Confidential 
  

																			
	 Docket
Number
	  	 Country
	  	 Case
Type
	  	 Status
	  	App
Owner	  	App No.	  	Filing Date	  	 Application Title
	  	Patent #	  	Issue Date
										
	 ***
	  	US	  	CON	  	Granted	  	LOCK	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	ORD	  	Granted	  	LOCK	  	***	  	***	  	***	  	***	  	***
										
	 ***
	  	US	  	CON	  	Granted	  	LOCK	  	***	  	***	  	***	  	***	  	***

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 69Heads of Agreement

 Exhibit 10.29 
 CONFIDENTIAL TREATMENT REQUESTED 
 Portions of this Exhibit have been redacted
pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended. Such redacted portions have been replaced with “[***]” in
this Exhibit. An unredacted version of this document has been filed separately with the Securities and Exchange Commission along with the request for confidential treatment 
 CONFIDENTIAL INFORMATION OF GENMARK AND ADVANCED LIQUID LOGIC, INC. 
 Heads of
Agreement 
 Clinical Micro Sensors, Inc. d/b/a GenMark Diagnostics, Inc. (“GenMark”) 

and Advanced Liquid Logic, Inc. (“ALL”) 
 March 30, 2012 
  

			
		
	 1.      Definitions
	  	
		
	 a.      Licensed IP
	  	All intellectual property owned or controlled by ALL, including patents and know-how, necessary or useful to make, have made, use, sell, offer for sale, or import Licensed Products
in the Field.
		
	 b.      Licensed Product
	  	Any product for use in Diagnostic Testing, including instruments and consumables, the manufacture, use, sale, offer for sale, or importation of which, would (but for a license from
ALL) infringe a valid patent claim of the Licensed IP.
		
	 c.      Territory
	  	Worldwide
		
	 d.      Field
	  	Protein Analyte Field and Molecular Analyte Field, and subject to exercise of the option described in 2c below, the Other Analyte Field.
		
	 (i)     Protein Analyte Field
	  	Human in-vitro Diagnostic testing using Genmark e-Detection of protein and/or peptide analytes.
		
	 (ii)    Molecular Analyte Field
	  	Human in-vitro Diagnostic testing using Electrochemical Detection of DNA, RNA or other nucleotide sequence analytes, excluding detection utilizing Sequencing (to be
defined).
		
	 (iii)  Other Analyte Field
	  	Human in-vitro Diagnostic testing using Genmark e-Detection of analytes other than: (i) proteins and/or peptides and (ii) DNA, RNA or other nucleotide sequences.
		
	 e.      Electrochemical Detection
	  	Use of at least two electrodes to apply potential and measure current produced by a chemical reaction occurring in a liquid in contact with the electrodes. For the sake of clarity,
Electrochemical Detection excludes detection methods which involve detection or measurement of conductivity, impedance or capacitance of a droplet, a portion of a droplet, or the contents of a droplet, as well as electrochemilimenescence and optical
means of detection.
		
	 f.       GenMark e-Detection
	  	Detection of an analyte based on a Complex where the Electrochemical Label is detected using Electrochemical Detection.
		
	 g.      Complex
	  	Complex comprising a capture ligand coupled to an electrode surface, a target analyte, and an Electrochemical Label
		
	 h.      Electrochemical Label
	  	Moieties that function in a Complex to produce an electrical signal (detected by the electrode) by oxidation or reduction of the moiety, including metal complexes of iron,
ruthenium, and osmium. For the sake of clarity, Electrochemical Label specifically excludes enzymatic labels (except as provided in the nonexclusive license granted in 2.c.) and labels that function by releasing hydrogen ions.
		
	 i.       Diagnostic
	  	Testing for the purpose of diagnosis, prognosis, monitoring, screening or predicting a disease or condition in a human, or selecting a therapeutic or prophylactic regimen; excluding
screening of newborn infants for metabolic or other disorders in fields other than in the Molecular Analyte Field using GenMark e-Detection.

  
 1 

 CONFIDENTIAL INFORMATION OF GENMARK AND ADVANCED LIQUID LOGIC, INC. 

 

			
		
	 j.       Collaboration Inventions
	  	All inventions and know-how (whether or not patentable) that are first invented (as that term is defined under U.S. Patent Laws) as a direct result of activities undertaken under
the Development Plan, including activities performed by a third party on a party’s behalf.
		
	 k.      Other Terms
	  	Capitalized terms not defined herein will be defined in the Definitive Agreements.
		
	 2.      Licenses
	  	The following licenses will be granted only upon execution of the Definitive Agreements:
		
	 a.      GenMark e-Detection Technology
	  	Exclusive license, under the Licensed IP, to make, have made, use, sell, offer for sale, and import for use in the Protein Analyte Field and Molecular Analyte Field those Licensed
Products utilizing GenMark e-Detection in the Territory.
		
	 b.      [***] Molecular Diagnostics
	  	Exclusive license, under the Licensed IP, to make, have made, use, sell, offer for sale, and import for use in the Molecular Analyte Field those Licensed Products utilizing
Electrochemical Detection [***] in the Territory.
		
	 c.      Enzyme Labels
	  	Nonexclusive license, under the Licensed IP, to make, have made, use, sell, offer for sale, and import for use in the Protein Analyte Field those Licensed Products utilizing
Electrochemical Detection [***] in the Territory where the Electrochemical Label is an enzyme.
		
	 d.      Option for Other Analyte Field
	  	GenMark shall have the option to obtain an exclusive license, under the Licensed IP, to make, have made, use, sell, offer for sale, and import for use in the Other Analyte Field
those Licensed Products utilizing GenMark e-Detection in the Territory. Such option shall be exercisable at any time within [***] ([***]) years of the effective date of the Definitive Agreements upon (i) the payment by GenMark of $[***] and (ii) the
agreement to pay a one-time $[***] milestone payment upon reaching $[***] of net sales of consumable Licensed Products for use in the Other Analyte Field.
		
	 3.      Right of First Refusal
	  	Following execution of the Definitive Agreements:
		
	 a.      [***] Molecular Diagnostics
	  	ALL grants GenMark a one-year right of first refusal to obtain a right or license under the Licensed IP in the Molecular Analyte Field for products using Electrochemical Detection
[***].
		
	 b.      Other In-Vitro Diagnostics
	  	For a period of [***] years, ALL will notify GenMark prior to licensing a third party for products in human in-vitro Diagnostic testing using Electrochemical Detection for targets
outside the Protein Analyte Field and the Molecular Analyte Field, excluding detection utilizing Sequencing (to be defined).
		
	 4.      Payments
	  	
		
	 a.      Equity Investment
	  	 •   $[***] shares of ALL preferred stock at signing of the Definitive Agreements (as defined below), subject
to due diligence, terms and a price to be agreed

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 2 

 CONFIDENTIAL INFORMATION OF GENMARK AND ADVANCED LIQUID LOGIC, INC. 

 

			
		
		  	 •   Rights to participate in future financing

 
 •   Terms of the equity
investment will be substantially equivalent to ALL’s series E, or if no series E has been issued, ALL’s series D, and will include an anti-dilution feature whereby GenMark will be awarded (at no cost to GenMark) more shares if there is a
subsequent financing at lower per-share price than the per-share price paid by GenMark.

		
	 b.      Cash Payments
	  	
		
	 (i)      Initial Payment
	  	$[***] at signing of the Definitive Agreements
		
	 (ii)     Milestone Driven Non-Equity Payments
	  	$[***] based on development milestones to be agreed, payments to be spread across the development period
		
	 5.      Royalties on Instrument Licensed Products
	  	
		
		  	[***]% of net capital sales of instrument Licensed Products
		
	 a.      Revenue Sharing
	  	The Definitive Agreements will include provisions protecting against shifting of sales revenue from Licensed Products to non-royalty bearing products.
		
	 6.      Product Development
	  	Following execution of the Definitive Agreements:
		
	 a.      Management
	  	A Joint Development Committee (“JDC”), consisting of representatives from GenMark and ALL, will be formed for the purpose of monitoring progress of under the Development
Plan (as defined below), and coordinate resources and efforts.
		
	 b.      Development Plan
	  	ALL shall perform certain activities supporting the development of Licensed Products utilizing ALL’s proprietary electrowetting according to a “Development Plan.” An
initial Development Plan will be appended to the Definitive Agreement and will describe the activities to be undertaken by ALL, and the timelines and budget therefor.
		
	 c.      Fees
	  	ALL’s activities under the Development Plan will be funded by GenMark, including reimbursement of ALL’s direct costs and indirect costs for such activities, which costs
shall be consistent with ALL’s auditable, DCAA approved rate structure.
		
	 7.      Component Supply
	  	Following execution of the Definitive Agreements:
		
		  	 •    Subject to agreed to terms regarding the continuity and quality of supply, ALL shall be the
exclusive supplier of the components of consumable Licensed Products that incorporate ALL’s proprietary electro-wetting technology. The price of each component of a consumable Licensed Product supplied over a given period will equal to the sum
of [***].

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 3 

 CONFIDENTIAL INFORMATION OF GENMARK AND ADVANCED LIQUID LOGIC, INC. 

 

			
		
		  	The price of the each component of a consumable Licensed Product supplied by ALL shall be subject to volume-based caps to be negotiated and based on the benchmarking of comparable
raw material and labor costs at such volumes.
		
	 8.      IP Ownership
	  	Following execution of the Definitive Agreements:
		
		  	 Collaboration Inventions shall be treated as follows: (i) ALL shall, subject to the rights and licenses granted to GenMark, solely own
all ALL Inventions; (ii) GenMark shall solely own all GenMark Inventions; and (iii) all inventions, other than ALL Inventions and GenMark Inventions shall be jointly owned by the parties.

 
 GenMark Inventions are those Collaboration Inventions that relate solely to
Electrochemical Detection and Collaboration Inventions that are apparatus that relate solely to Electrochemical Detection.
  
 ALL Inventions are those Collaboration Inventions that relate solely to digital microfluidics (to be defined).

		
	 9.      Other Terms
	  	
		
		  	The Definitive Agreements will include other customary terms and conditions contained in similar agreements of the type. These will include, for example, diligence requirements,
co-branding of products, confidentiality, auditing rights, representations and warranties, dispute resolution, and termination.
		
	 10.    Binding Nature
	  	
		
		  	ALL and GenMark shall enter into one or more agreements reflecting the terms and conditions set forth in this Heads of Agreement and other terms mutually agreeable to the parties
(“Definitive Agreements”). ALL and GenMark agree to negotiate diligently and in good faith to prepare and execute such Definitive Agreements as soon as practicable. Pending execution of the Definitive Agreements, this Heads of Agreement
shall be deemed a legally binding obligation of the parties hereto. Upon termination of this Heads of Agreement as provided for in Section 11 (Effective Date), all provisions of this Heads of Agreement will be null and void, and except for the
provisions of Section 15 (Confidentiality), no provision of this Heads of Agreement shall survive expiration or termination.
		
	 11.    Effective Date
	  	
		
		  	 This Heads of Agreement shall commence on the Effective Date (as defined below), and shall terminate upon the earlier of:

 
 (A)     execution
by the parties of the Definitive Agreements;
  
 (B)     agreement by the parties in writing; or
  

(C)     failure to obtain [***] written consent for ALL to enter into the Definitive
Agreements prior to the expiration of the Negotiation Period (as defined below).

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 4 

 CONFIDENTIAL INFORMATION OF GENMARK AND ADVANCED LIQUID LOGIC, INC. 

 

			
		
	 12.    Representations & Warranties
	  	
		
		  	 Each party hereby represents and warrants that, as of the Effective Date, it has the full right and authority, and has obtained all
approvals, permits or consents necessary, to enter into this Heads of Agreement, and to perform all of its obligations hereunder.
  

ALL has not, prior to the date hereof, entered into and shall not, following the date hereof and prior to the expiration of this Heads of Agreement, enter
into any agreement and has not granted any now existing, or agreed to grant any future, license, right or privilege which agreement, license, right or privilege conflicts in any way with this Heads of Agreement, the rights and licenses granted to
GenMark hereunder, or ALL’s obligations hereunder.
  
 Notwithstanding
the terms of this Section 12, GenMark acknowledges that it will be necessary for ALL to obtain written consent from [***] prior to completion of the Definitive Agreements. ALL represents and warrants that is will use its best efforts to obtain any
and all consents from [***] required to enter into the Definitive Agreements within thirty (30) days of the Effective Date.

		
	 13.    Miscellaneous
	  	
		
		  	This Heads of Agreement shall be governed by and construed under the laws of the State of Delaware, without regard to the conflict of laws provisions thereof. This Heads of
Agreement may be executed in one or more counterparts, each of which shall constitute one and the same Agreement. For purposes of executing this agreement, a facsimile copy of this Heads of Agreement, including the signature pages, will be deemed an
original. This Heads of Agreement has been prepared jointly and no rule of strict construction shall be applied against either party. In this Heads of Agreement, the singular shall include the plural and vice versa and the word “including”
shall be deemed to be followed by the phrase “without limitation.” The section headings contained in this Agreement are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Heads of
Agreement.
		
	 14.    Arbitration
	  	
		
		  	If, despite the diligent and good faith efforts of the parties, for a period of at least one hundred eighty (180) days from the Effective Date (“Negotiation Period”), the
parties are unable to prepare and execute the Definitive Agreements reflecting the terms and conditions set forth in this Heads of Agreement, then either party may submit the matter to final and binding arbitration under the auspices of the American
Arbitration Association (“AAA”). Unless otherwise agreed to by the parties, any such arbitration shall be conducted in San Diego, California pursuant to the then-current commercial arbitration rules of the AAA, as modified herein. Such
arbitration shall be conducted in the English language. The arbitration tribunal shall consist of a single arbitrator who is an independent expert in worldwide business development in the diagnostics industry, mutually acceptable to the parties. If
the parties are unable to agree on an arbitrator, the arbitrator shall be an independent expert as described in the preceding sentence selected by the chief executive of the San Diego office of the
AAA.

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 5 

 CONFIDENTIAL INFORMATION OF GENMARK AND ADVANCED LIQUID LOGIC, INC. 

 

			
		
		  	 Any such arbitration hereunder shall be a “baseball” type arbitration. Accordingly, notwithstanding the commercial arbitration
rules of the AAA, each party shall provide to the arbitrator, and the other party, its proposed version of the Definitive Agreements. Each party may submit a revised version of its proposed Definitive Agreements to the arbitrator and the other party
within thirty (30) days after receiving the other party’s initial proposal. If so requested by the arbitrator, each party shall make oral submissions to the arbitrator based on such party’s proposal; provided that other party shall have
the right to be present during any such oral submissions. The arbitrator shall select one party’s proposed Definitive Agreements as his or her decision, and shall not have the authority to render any substantive decision other than to select
the proposal submitted by either GenMark or ALL (as initially submitted, or as revised in accordance with the foregoing, as applicable). The parties shall use diligent efforts to complete any arbitration within sixty (60) days following a request by
a party for such arbitration.
  
 The administrative charges,
arbitrator’s fees, and related expenses of any arbitration shall be shared equally by the parties, but each party shall be responsible for its own expenses in connection with such arbitration (including its own attorneys’ fees).

 
 The decision of the arbitrator shall be the binding remedy between the parties
regarding the dispute presented to the arbitrator. Any decision of the arbitrator may be entered in a court of competent jurisdiction for judicial recognition of the decision and an order of enforcement.

Pending the selection of the arbitrator or pending the arbitrator’s determination of the merits of any arbitration, either party may seek appropriate
interim or provisional relief from any court of competent jurisdiction as necessary to protect the rights or property of that party.

		
	 15.    Confidentiality
	  	
		
		  	During the course of this Heads of Agreement, the parties may receive from each other information which is proprietary and confidential to the party disclosing such information.
Such information, as well as the existence of and terms of this Heads of Agreement, shall be deemed “Proprietary Information” as that term is used in the Mutual Confidentiality Agreement between the parties and effective June 30, 2010
(“Mutual CDA”), and shall be subject to the terms and provisions of the Mutual CDA. Further, the Purpose of the Mutual CDA is hereby amended to include the exchange of information relevant to the this Heads of Agreement, negotiation of the
Definitive Agreements, and the business relationships contemplated thereby.

 * * * * * 
  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted
portions. 

  
 6 

 CONFIDENTIAL INFORMATION OF GENMARK AND ADVANCED LIQUID LOGIC, INC. 

 

 IN WITNESS WHEREOF, the parties have caused this Heads of Agreement to be executed
by their duly authorized representatives as of this 30th
day of March, 2012 (“Effective Date”). 

 

			
	Clinical Micro Sensors, Inc.
		
	By:	 	 /s/ Hany Massarany

			
	Name:	 	 Hany Massarany

			
	Title:	 	 President and CEO

 

			
	Advanced Liquid Logic, Inc.
		
	By:	 	 /s/ Richard M. West

			
	Name:	 	 Richard M. West

			
	Title:	 	 President and CEO

 
 

  
 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}]]